The U.S. Food and Drug Administration (FDA) has accepted to review Emergent BioSolutions’ (NYSE:EBS) Biologics License Application (BLA) for its new anthrax vaccine candidate AV7909.
The regulatory agency sets the Prescription Drug User Fee Act (PDUFA) goal date for a decision in month of April 2023.
